LexaGene Announces Completion of its Previously Announced Non-Brokered Private Placement

Company is pleased to announce the completion of its previously announced non – brokered private placement pursuant to which the Company has issued 8,400,800 common shares in the capital of the Company (the “Shares”) at a price of $0.25 per Share for aggregate gross proceeds of $2,100,200 (the “Offering”). The Offering was conducted pursuant to the Company’s acquisition of all issued and outstanding securities of Bionomics Diagnostics Inc., structured as a Reverse Takeover under the rules and policies of the TSX Venture Exchange (the “Transaction”).

VIEW RELEASE